月份: 2026 年 3 月

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 5, 2026) - Lancaster Resources Inc. (CSE: LCR) (OTC Pink: LANRF) (FSE: 6UF0) ("Lancaster" or the "Company") announces the director resignation of Penny White, effective March 3, 2026. The Board thanks Penny White for her valuable contributions during her tenure and wishes her continued success in her future endeavors.The Company is also pleased to announce the appointment of Mr. Rob Heaslop, as a director to the company's Board of Directors, effective immediately.Mr. Heaslop is a geologist with 20 years' of exploration and resource development experience in Africa, Australia, and the Pacific with specific expertise in project generation and early stage targeting for precious and base metal deposits. Mr. Heaslop holds a Bachelor of Science (Hons) from The University of Queensland majoring in earth science and geology, and during his career has worked for major, junior, and private exploration and mining companies. In 2016, Mr. Heaslop founded his privately owned project generation company, MRG Resources Pty Ltd, that has created significant value identifying exploration opportunities in Australia, including deals with major and mid-tier mining houses and private exploration companies. Mr. Heaslop is a member of the Australasian Institute of Mining and Metallurgy (MAusIMM), Australian Institute of Geoscientists (MAIG), and the Society of Economic Geologists (SEG)."We are thrilled to welcome Mr. Heaslop to the Board," said Andrew Watson, President & CEO of Lancaster Resources. "His technical expertise will be invaluable as Lancaster continues to develop our Lake Cargelligo gold project, Lac Iris polymetallic asset, and our other critical and precious mineral assets."Rob Heaslop commented, "I am focused on the opportunities ahead and committed to help navigate a successful exploration program for our projects and shareholders. I am truly excited to continue working with the team here."The new board appointment reflects Lancaster Resources' transition to a new corporate direction and commitment to strengthening its leadership and strategic capabilities to enhance shareholder value and propel the company's growth in the mining industry.Andrew Watson, P.Eng., President & CEO and a Director of the Company, is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Watson has reviewed and approved the scientific and technical information contained in this news release. Mr. Watson is a Director and the President and CEO of Lancaster and is not independent of the Company.About Lancaster Resources Inc. Lancaster Resources Inc. is a Canadian exploration company advancing a diversified portfolio of gold and silver exploration projects in established mining jurisdictions. The Company holds a 100% interest in the Lake Cargelligo Gold Project in New South Wales, Australia, which is prospective for both gold and silver mineralization, covering approximately 62,300 hectares with a history of drilling and exploration and multiple high-priority targets. In Canada, Lancaster's assets include the Lac Iris Polymetallic Project in Quebec's James Bay region and the Piney Lake Gold Project in Saskatchewan. Lancaster's portfolio provides exposure to gold, silver, and polymetallic exploration opportunities across tier-one jurisdictions.Andrew Watson, President & Chief Executive Officer,Lancaster Resources Inc.Andrew@Lancaster-Resources.comTel: (604) 923-6100www.lancaster-resources.comThe Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release. Cautionary Statement Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events, or Lancaster's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lancaster's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, the ability of Lancaster to execute its exploration plans, raise capital, retain key personnel, identify, acquire, explore, and develop high-quality mineral-rich properties constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Lancaster disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286260 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.About CMS-D008CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solutionCMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564.2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=233. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年3月5日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，其自主研發的創新藥INHBE小核酸藥物CMS-D008注射液（「CMS-D008」）於2026年3月4日獲得中國國家藥品監督管理局（「NMPA」）簽發的藥物臨床試驗批准通知書。NMPA同意開展CMS-D008注射液用於超重或肥胖的臨床試驗。關於CMS-D008CMS-D008是一款皮下注射的siRNA藥物，靶向抑制肝臟的抑制素亞基βE（INHBE）基因表達，下調INHBE編碼蛋白激活素E（Activin E）水平，從而降低脂肪代謝通路Activin E-ALK7的活化，有效減少脂質堆積。臨床前研究提示CMS-D008高效持續抑制INHBE表達，肥胖動物模型中，在不影響肌肉的情況下，獲得明顯的減重減脂效果，且安全性良好；顯示減脂不減肌，長期高質量減重的良好前景。未來可開發治療超重/肥胖，腹型肥胖以及相關代謝性疾病。減脂不減肌，超重/肥胖的潛在更優治療方案超重或肥胖是一種脂肪組織過度積累或分布、功能異常的慢性、進行性、複發性疾病[1]。根據《2025年世界肥胖報告》，預測到2030年，全球超重和肥胖成年人的比例會上升到50%，將有近30億成年人受到高體重指數（BMI）的影響，我國成人超重/肥胖人數將達到5.15億[2]。現有的GLP-1RA類藥物顯示了很好的減重效果，該類藥物主要通過作用於中樞神經系統抑制食欲，延緩胃排空來降低體重[3]，而INHBE不同於GLP-1類藥物的作用機制，是從全基因組關聯分析篩選獲得，INHBE功能喪失的人群擁有良好的體脂分布和有利的代謝特征[4]，靶向抑制INHBE可以從基因水平精准減少內臟脂肪，改善代謝狀態，更有利於長期體重管理。 CMS-D008攜手CMS-D005：高效減重與長期維持聯合發力，構建更全面減重方案CMS-D008將與正處於臨床開發階段的自研創新藥CMS-D005形成協同，CMS-D008通過精准抑制INHBE基因表達，減脂不減肌；而CMS-D005作為GLP-1R/GCGR雙重激動劑，可在減重同時，強效降低肝臟脂肪，二者協同實現高效的減重獲益與長期的成果維持，共同增強康哲藥業在肥胖/代謝治療領域的研發實力與產品競爭力，並依託其在心血管代謝疾病領域成熟的網絡資源，加速藥物的研發與商業化進程，為患者提供更全面、創新的治療方案。康哲藥業正積極準備開展相關臨床試驗工作，力爭該產品儘快上市。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.中華醫學會內分泌學分會.肥胖患者的長期體重管理及藥物臨床應用指南(2024版).中華內分泌代謝雜誌,2024,40(7):545-564.2.世界肥胖聯盟. 《2025 年世界肥胖報告》[EB/OL]. 倫敦：世界肥胖聯盟，2025. https://data.worldobesity.org/publications/?cat=233.Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z4.Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CLEVELAND, Ohio, Mar 4, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, LLC ("Formerra"), a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials, today announced the appointment of Tom Kelly as Chief Executive Officer ("CEO"). A seasoned executive with over 30 years of specialty and engineered materials experience, Tom is known for leading teams to drive differentiated growth and building high-performing organizations set up for long-term success. The former CEO, Cathy Dodd, will stay on as Special Advisor to the Board and will remain an investor in the Company.Tom brings extensive commercial, supply chain, and distribution experience with a strong background in scaling global enterprises in the engineered materials sector. After previous roles at Cabot Microelectronics and Chemtura, Tom's most recent role was Senior Vice President of Engineered Materials at Celanese, where he led key commercial and operational initiatives across engineered polymers and specialty segments. He brings a strong blend of leadership, industry insight, and supply-chain expertise to his new role as CEO of Formerra."Formerra has built a tremendous reputation as a technical selling organization and for putting customers first, supported by exceptional people and supplier partners in the engineered materials ecosystem," said Tom Kelly. "I'm excited about the opportunity to build on its strengths and accelerate capabilities in new geographies and adjacent materials. We will continue investing in our people, distribution network, and in our product line card to strengthen Formerra's competitive position globally."About FormerraFormerra, headquartered in Cleveland, Ohio, is a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials. Formerra supports leading blue-chip customers and suppliers with its extensive specialty materials portfolio and value-added combination of commercial and technical expertise, global market knowledge, and industry-leading logistics and service capabilities. Formerra offers highly specialized technical, processing, design and regulatory support for critical end market applications in the healthcare, consumer, industrial and mobility markets. Formerra operates an asset-light network of 37 warehouses and 21 bulk transfer stations located in North America, Central America, Europe, and Asia.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

美國俄亥俄州克里夫蘭, 2026年3月4日 - (亞太商訊 via SeaPRwire.com) - 領先的工程熱塑性樹脂、添加劑、彈性體及其他特種材料分銷商 Formerra, LLC（“Formerra”）今日宣布任命 Tom Kelly 為公司首席執行官（CEO）。Tom 是一位資深高管，在特種材料和工程材料領域擁有超過30年的經驗，以帶領團隊推動差異化增長並打造具備長期成功基礎的高績效組織而聞名。公司前任首席執行官 Cathy Dodd 將繼續擔任董事會特別顧問，並將繼續作為公司的投資者。Tom 在工程材料領域擁有豐富的商業、供應鏈和分銷經驗，並在推動工程材料行業全球企業規模化發展方面具備深厚背景。在曾任職於 Cabot Microelectronics 和 Chemtura 之後，Tom 最近擔任 Celanese 工程材料部門高級副總裁，負責領導工程聚合物和特種材料領域的關鍵商業及運營舉措。在擔任 Formerra 首席執行官的新角色中，他將憑藉卓越的領導能力、深厚的行業洞察以及供應鏈專業經驗，推動公司持續發展。Tom Kelly 表示：“Formerra 作為一家技術型銷售組織，並始終堅持以客戶為中心，在工程材料生態體系中與優秀的員工和供應商夥伴共同建立了卓越的聲譽。我很高興有機會在這一堅實基礎上繼續發展，並在新的地域市場和相關材料領域加速拓展能力。我們將繼續投資於人才、分銷網絡以及產品組合，以進一步增強 Formerra 在全球市場的競爭地位。”關於 FormerraFormerra 總部位於美國俄亥俄州克利夫蘭，是一家領先的工程熱塑性樹脂、添加劑、彈性體及其他特種材料分銷商。憑藉其豐富的特種材料產品組合，以及商業與技術專長、全球市場洞察以及行業領先的物流與服務能力的增值整合，Formerra 為眾多知名藍籌客戶和供應商提供支持。Formerra 還為醫療保健、消費品、工業及出行等關鍵終端市場應用提供高度專業化的技術、加工、設計及法規合規支持。目前，Formerra 在北美、中美洲、歐洲和亞洲運營著一個輕資產網絡，包括 37 個倉庫和 21 個散裝中轉站。媒體聯絡Jackie Morris Marketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144來源: Formerra Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月4日 - (亞太商訊 via SeaPRwire.com) - 由香港貿易發展局（香港貿發局）主辦的第42屆香港國際珠寶展，今日起一連五日（3月4至8日）在灣仔香港會議展覽中心舉行，而第12屆香港國際鑽石、寶石及珍珠展已率先於周一（3月2日）在亞洲國際博覽館揭幕，展期至3月6日。兩展雲集逾40個國家及地區、約4,000家展商，組成全球最大一站式珠寶商貿平台。香港貿發局副總裁古靜敏表示：「今年香港國際珠寶展的品牌精粹廊規模進一步擴大，更首設硬足金展館及香港表廠商會展館。烏茲別克亦首次組團參展，帶來10家企業展示黃金珠寶產品。我們期望透過多元化的展會內容，為業界開拓更多合作機會，進一步鞏固香港作為國際珠寶貿易樞紐的地位。」香港國際珠寶展及香港國際鑽石、寶石及珍珠展籌備委員會主席黃紹基表示：「香港作為國際商貿及採購中心，香港貿發局珠寶雙展發揮著舉足輕重的作用。今年延續『兩展兩地』的成功模式，吸引世界各地珠寶業人士前來參觀採購，相信有助業界拓展國際商機，並掌握環球市場最新動向。」國際品牌雲集 焦點展區陣容升級香港國際珠寶展備受矚目之一的品牌精粹廊(Hall of Fame)展區規模較往年擴大逾四成，其中的土耳其展商 Hosgor Kuyumculuk Mucevherat Ticaret Limited Sirketi（展位：會展 3B-D15）於展會帶來35.5卡鑽石頸錬，工藝與光芒兼備。另一焦點展區珠寶精粹廊(Hall of Extraordinary)同樣精彩，香港展商駿邑國際(Glamour Fine Jewelry Enterprise Company)（展位：會展 GH-C16）帶來以哥倫比亞祖母綠配襯鑽石及紅寶石的手鍊，呈現華麗氣派。首設展館展示東方美學內地近年興起硬足金技術，世界黃金協會組織11家企業於硬足金展館展出（展位：會展 3E-F02），向國際展示硬足金嶄新工藝，相比傳統足金飾品更硬、更輕、更亮，能夠鑲嵌不同寶石物料，迎合時尚珠寶潮流。此外，香港表廠商會展館亦會重點展示珠寶與腕表的跨界工藝。展會期間舉行多場關於東方美學珠寶的活動，包括今日舉行的香港國際時尚足金首飾設計比賽頒獎典禮，比賽以「黃金新思路‧新絲路的文化交融與創新」為主題，鼓勵設計師創作出迎合東盟及中東市場，兼具文化內涵和商業潛力的金飾作品。明天（3月5日）將舉行國際翡翠玉器首飾設計大賽頒獎典禮，表揚將翡翠玉石與國際文化結合的優秀設計人才。古董珍藏與設計新銳古典首飾向來深受收藏家及高端客群青睞，其歷史價值與經典工藝亦令作品別具收藏價值。古典精粹廊（Antique & Vintage Jewellery Galleria）展出多件古董珍品，包括展商World Coins Co., Ltd.（展位：會展CH‑N12）帶來的一套擁有超過100年歷史的雙色琺琅鑽石首飾。別具匠心的設計同樣極具吸引力，珠寶設計精選展區（Designer Galleria）今年特別邀請十位韓國設計師參與，連同新晉珠寶設計師專區（Young Jewellery Designer Arena）、亞太區創作師協會以及亞洲珠寶文化設計工藝協會，合共匯聚約50家設計師展商，展示多元創意。香港貿發局一向致力培育香港珠寶設計人才，並積極推動珠寶業的創意發展，今年再次與香港珠寶首飾業商會、香港珠寶玉石廠商會、香港珠寶製造業廠商會及香港鑽石總會攜手舉辦第27屆香港珠寶設計比賽，以「未琢之韻．自然之美」為題，讓本地專業珠寶設計師及學生一展才華。頒獎典禮將於明天（3月5日）於會展舉行，獲奬作品展示創新的珠寶設計。電商與科技助力行業發展為協助展商開拓中國內地市場及線上銷售渠道，今年展會繼續與電商平台淘寶天貓合作，同時抖音亦會首次參與，聯同網紅達人在現場為參展商進行產品直播。大會將於3月7日舉辦研討會，由業界專家及網紅剖析最新線上營銷趨勢及技巧。此外，針對創新科技對珠寶行業的影響，3月5日舉辦的研討會將探討人工智能及新技術如何協助業界提升競爭力、優化生產效率及推動產品創新。精彩活動促進業界交流展會期間將安排多場專題活動，包括由英國歷史學家及珠寶權威Dr. Jack Ogden主講的研討會，深入分析珠寶工藝的演變。多場珠寶匯演將展示不同主題系列，包括非物質文化遺產珠寶、古典精粹廊精選、珠寶精粹廊精選、設計師精選，以及黃金首飾。香港國際時尚足金設計比賽完整得獎名單：https://bit.ly/46B5edL圖片下載：https://bit.ly/46GadtL由香港貿易發展局主辦的第42屆香港國際珠寶展今日於灣仔會展隆重開幕，連同於亞博館舉行的第12屆香港國際鑽石、寶石及珍珠展，共匯聚來自全球超過40個國家及地區，約4,000家參展商。香港工業總會主席林世豪（前排正中）、香港特別行政區政府商務及經濟發展局副局長陳百里（前排右五）、香港貿發局總裁張淑芬（前排左五）、香港國際珠寶展及香港國際鑽石、寶石及珍珠展籌備委員會主席黃紹基（前排右四）、香港貿發局珠寶業諮詢委員會主席周允成（前排左四）及一眾嘉賓，出席今日（3月4日）舉行的第42屆香港國際珠寶展及第12屆香港國際鑽石、寶石及珍珠展交流酒會。今年「品牌精粹廊」展區規模較去年擴大逾四成，匯聚更多國際知名珠寶品牌。世界黃金協會於珠寶展首設硬足金展館，合共11家展商，向國際展示硬足金嶄新工藝。香港表廠商會展館首度登場，展出多款結合珠寶鑲嵌工藝的奢華腕錶系列。中國内地展商賽菲爾珠寶（展位：會展 3E-E02）帶來主打「東方宮廷」與「新中式」風格，運用六種古法黃金工藝製作的24K黃金項鏈。香港展商比辰鐘錶珠寶（展位：會展 1CON-019）帶來一款以北宋名作《愛蓮說》為設計靈感的鑽石手表，將表面打造成蓮花池一樣。土耳其展商Zen Diamond（展位：會展 3B-C12）於2025年邀請國際名人Jennifer Lopez擔任全球代言人，今次為珠寶展帶來一系列的鑽石作品。香港設計師Austy Lee（展位：會展 1E - F32）趁馬年推出以斑馬為靈感的手鐲，別出心裁。「香港國際時尚足金設計比賽」一眾得獎者與嘉賓合照。展會資料：香港國際珠寶展展覽日期開放時間3月4日（星期三）上午10時30分至下午6時30分3月5至7日（星期四至六）上午10時至下午6時30分3月8日（星期日）上午10時至下午5時30分展覽地點灣仔博覽道1號香港會議展覽中心記者登記處及新聞中心新聞界代表請攜同名片及記者證到香港會議展覽中心展覽廳1D大堂，或到香港貿發局新聞中心（香港會議展覽中心博覽道入口──新翼地下）即場辦理記者入場證** 香港國際鑽石、寶石及珍珠展展覽日期開放時間3月2日(星期一)上午10時30分至下午6時30分3月3至5日 (星期二至四)上午10時至下午6時30分3月6日 (星期五)上午10時至下午5時30分展覽地點香港大嶼山香港國際機場亞洲國際博覽館記者登記處及新聞中心新聞界代表請攜同名片及記者證到亞洲國際博覽館東大堂入口 （5號展館門口旁），或到新聞中心（2樓201B會議室）即場辦理記者入場證****基於保安理由，記者須出示工作證及身份證或護照登記，方能辦理記者證，持大會發出記者證入場前，保安人員亦會要求出示身份證明文件，以確認身份。請預留足夠時間辦理記者證及入場。相關網頁 香港國際珠寶展香港國際鑽石、寶石及珍珠展展覽網頁http://hkjewelleryshow.hktdc.com/tchttp://hkdgp.hktdc.com/tc兩展穿梭巴士安排https://www.hktdc.com/event/hkjewllery/tc/travel-to-fairground-hkcechttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-awe展會活動https://www.hktdc.com/event/hkjewellery/tc/intelligence-hubhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hub香港貿發局新聞中心：http://mediaroom.hktdc.com/tc傳媒查詢香港貿易發展局傳訊及公共事務部：簡惠宜電話：(852) 2584 4055電郵：winnie.wy.kan@hktdc.org黃家欣電話：(852) 2584 4524電郵：katy.ky.wong@hktdc.org張敏萱電話：(852) 2584 4137電郵：jane.mh.cheung@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構，負責促進、協助和發展香港貿易。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 4, 2026 - (ACN Newswire via SeaPRwire.com) – The 42nd Hong Kong International Jewellery Show, organised by the Hong Kong Trade Development Council (HKTDC), opens today at the Hong Kong Convention and Exhibition Centre (HKCEC) and runs for five consecutive days until 8 March. It is held concurrently with the 12th Hong Kong International Diamond, Gem & Pearl Show which opened on Monday (2 March) at AsiaWorld-Expo and concludes on 6 March. The two shows bring together some 4,000 exhibitors from over 40 countries and regions, forming the world’s largest one-stop jewellery marketplace.Jenny Koo, Deputy Executive Director of the HKTDC, said: “Alongside the expanded Hall of Fame, the show will feature the debut of the Hard Pure Gold Pavilion and the Hong Kong Watch Manufacturers Association Pavilion. Furthermore, Uzbekistan is participating for the first time with a delegation of 10 companies, showcasing a wide range of gold jewellery. Through diversified exhibit profiles, we aim to create more collaboration opportunities for the industry and reinforce Hong Kong’s status as a global jewellery trading hub.”Kent Wong, Chairman of the Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem & Pearl Show Fair Organising Committee, said: “Hong Kong is an international trade and sourcing centre and our twin jewellery shows play a pivotal role. Continuing the successful ‘Two Shows, Two Venues’ format, the fairs attract global jewellery professionals for sourcing and networking, helping the industry capture the latest global market trends.”International brands converge, key zones expandAt the Hong Kong International Jewellery Show, the Hall of Fame has expanded by over 40%, welcoming more renowned international jewellery brands. Among them, Turkish exhibitor Hosgor Kuyumculuk Mucevherat Ticaret Limited Sirketi (Booth: CEC 3B-D15) presents a 35.5-carat diamond necklace that combines exquisite craftsmanship with brilliant radiance. Another highlight is the Hall of Extraordinary, which features exhibitors such as Hong Kong’s Glamour Fine Jewelry Enterprise Company (Booth: CEC GH-C16), showcasing a bracelet featuring Colombian emeralds paired with diamonds and rubies in a radiant and luxurious style.New pavilions highlight oriental aestheticsWith hard pure gold technologies gaining popularity in the Chinese Mainland, the Hard Pure Gold Pavilion (Booth: CEC 3E-F02) features 11 exhibitors organised by the World Gold Council. The pavilion showcases innovative techniques that produce harder, lighter and brighter gold pieces capable of setting a variety of gemstones. Also, the Hong Kong Watch Manufacturers Association Pavilion highlights crossover craftsmanship between jewellery setting and watchmaking.The fairs also feature several events celebrating oriental aesthetics. Today, the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited presented the awards for the Hong Kong International Fashion Chuk Kam Jewellery Design Competition. The competition encourages designers to create culturally rich and commercially viable gold jewellery for the ASEAN and the Middle East markets. Tomorrow (5 March) will see the awards presentation of the inaugural International Fei Cui Jewellery Design Competition, organised by the Hong Kong Jade Association, honouring designers who skilfully blend jadeite with global cultural elements.Antique treasures and cutting-edge designAntique jewellery remains highly sought-after by collectors and high-end customers for its historical value and craftsmanship. The Antique & Vintage Jewellery Galleria presents an array of rare pieces, including a bi-colour enamel diamond piece from World Coins Co., Ltd. (Booth: CEC CH-N12), with a history spanning over a century. Design pieces are equally captivating, the Designer Galleria welcomes 10 Korean designers this year. Together with the Young Jewellery Designer Arena, participated by the Asia Pacific Creator Association and the Asia Jewelry Culture Design and Crafts Association, about 50 designer exhibitors will showcase their diverse creativities in the fairground.The HKTDC continues to nurture local talents in the jewellery industry. In partnership with the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, Hong Kong Jewellery & Jade Manufacturers Association, Hong Kong Jewelry Manufacturers’ Association, and Diamond Federation of Hong Kong, the 27th Hong Kong Jewellery Design Competition returns under the theme “Pure Elegance – Natural Beauty”, offering a stage for local professional designers and students. The awards ceremony will be held tomorrow (5 March) at the HKCEC, with winning pieces on display to demonstrate innovative design.E-commerce and technology empower industry growthTo help exhibitors expand into the Chinese Mainland market and develop their online sales channels, the fairs continue the collaboration with Taobao Tmall. For the first time, the fairs also welcome Douyin, partnering with influencers and KOLs for on-site live streaming to promote exhibitors’ products. On 7 March, a seminar will feature experts discussing the latest online marketing trends and tactics.Another seminar on 5 March will explore how AI and new technologies enhance competitiveness, optimise production, and drive product innovation in the jewellery industry.Engaging events to connect and inspireA diverse lineup of events will be held to foster industry dialogue. These include a seminar by Dr Jack Ogden, a distinguished British historian and jewellery authority, who will analyse the evolution of jewellery craftsmanship and changing aesthetic tastes throughout history. The jewellery parades will highlight themes such as intangible cultural heritage jewellery, curated selections from the Antique & Vintage Jewellery Galleria, as well as highlights from the Hall of Extraordinary, Designer Galleria, and gold jewellery.Full list of the winning entries from Hong Kong International Fashion Chuk Kam Jewellery Design Competition: https://bit.ly/46B5edLPhoto download: https://bit.ly/46GadtLThe 42nd Hong Kong International Jewellery Show opens today at the HKCEC, alongside the 12th Hong Kong International Diamond, Gem & Pearl Show at AWE, together gathering around 4,000 exhibitors from over 40 countries and regionsAnthony Lam, Chairman of the Federation of Hong Kong Industries (front row, centre); Bernard Chan, Under Secretary for Commerce and Economic Development (front row, fifth right); Sophia Chong, Executive Director of the HKTDC (front row, fifth left); Kent Wong, Chairman of the HKTDC twin jewellery shows’ Fair Organising Committee (front row, fourth right); Winston Chow, Chairman of the HKTDC Jewellery Advisory Committee (front row, fourth left), and other officiating guests attended today’s networking receptionThe Hall of Fame has expanded by over 40% this year, featuring more international brandsThe World Gold Council debuts the Hard Pure Gold Pavilion, featuring 11 exhibitors to showcase innovative hard pure gold craftsmanship to international buyersThe Hong Kong Watch Manufacturers Association Pavilion makes its first appearance, exhibiting luxury timepieces that integrate jewellery setting craftsmanshipShenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02) presents 24K gold necklaces themed around oriental palatial and modern Chinese styles, employing six traditional gold techniquesHong Kong exhibitor Present Watch & Jewelry (Booth: CEC 1CON-019) showcases a diamond wristwatch inspired by the Northern Song masterpiece “Ode to the Lotus”, with a dial crafted to evoke a lotus pondTurkish brand Zen Diamond (Booth: CEC 3B-C12), which appointed global celebrity Jennifer Lopez as its ambassador in 2025, presents a series of diamond pieces at the showHong Kong designer Austy Lee (Booth: CEC 1EF32) launches a zebra-inspired-bangle for the Year of the HorseWinners of the Hong Kong International Fashion Chuk Kam Jewellery Design Competition pictured at the award ceremony with distinguished guestsFair detailsHong Kong International Jewellery ShowDateOpening hours4 March (Wednesday)10:30am to 6:30pm5-7 March (Thursday to Saturday)10am to 6:30pm8 March (Friday)10am to 5:30pmVenueHong Kong Convention and Exhibition Centre, 1 Expo Drive, Wan ChaiPress registration and Media CentreMedia representatives can register at the entrance of HKCEC Hall 1D Concourse, or at the HKTDC Media Centre (G/F, Expo Drive Entrance, HKCEC) by presenting a business card or media identification.* Hong Kong International Diamond, Gem & Pearl ShowDateOpening hours2 March (Monday)10:30am to 6:30pm3-5 March (Tuesday to Thursday)10am to 6:30pm6 March (Friday)10am to 5:30pmVenueAsiaWorld-Expo, Hong Kong International Airport, Lantau, Hong KongPress registration and Media CentreMedia representatives can register at the entrance of AsiaWorld-Expo’s East Lobby (Next to Hall 5) or at the Media Centre (Room 201C, 2/F) by presenting a business card or media identification.** For security reasons, all media will be required to present a name card and identity card (or passport) for press registration. Individuals with a valid press pass will be required to present their identity card (or passport) again at the entrance to the exhibition halls for identity verification. Please allow sufficient time for registration and admission.Websites Hong Kong International Jewellery ShowHong Kong International Diamond, Gem & Pearl ShowWebsitehttp://hkjewelleryshow.hktdc.comhttp://hkdgp.hktdc.comActivity listhttps://www.hktdc.com/event/hkjewellery/en/intelligence-hubhttps://www.hktdc.com/event/hkdgp/en/intelligence-hubShuttle bus arrangementshttps://www.hktdc.com/event/hkjewellery/en/travel-to-fairground-hkcechttps://www.hktdc.com/event/hkdgp/en/travel-to-fairground-aweHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) - Core Concepts Physio, one of Singapore's leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain.Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved.To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked.A Smarter, More Complete Way to Diagnose Heel PainPhysiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support.The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in:More accurate, holistic diagnosesFully optimised treatment strategiesFewer flare-ups and recurrencesClearer, consistent guidance for patientsFaster and more sustainable outcomes"Many patients struggle because plantar fasciitis isn't caused by just one issue," said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. "It's a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms."A Case Study Demonstrating Collaborative SuccessIn a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts.A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient's daily load decreased significantly — allowing physiotherapy progress to continue without setbacks.Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running."This case reflects what we see frequently," said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. "Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery."Making Multidisciplinary Care Accessible NationwideThrough this collaboration, patients with plantar fasciitis now benefit from:Joint physiotherapy–podiatry assessmentsAligned clinical decision-makingConsistent communication across providersA thorough evaluation of both the cause and consequence of heel painA fully optimised recovery pathway"Our multidisciplinary team brings together the best of both professions," said Mr Chng Chye Tuan. "Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands."About Core Concepts PhysiotherapyCore Concepts Physio is one of Singapore's largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580.About Podiatry QuestPodiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care.Contact DetailsOrganization: Core Concepts Pte LtdContact: Clemence LimWebsite: https://www.coreconceptsphysio.sg Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

東京, 2026年3月5日 - (亞太商訊 via SeaPRwire.com) - 以TANAKA的產業用貴金屬展開事業的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（總公司：東京都中央區，執行總裁：田中 浩一朗）宣布成功開發出可於100℃左右的低溫範圍內使用的濾氫鈀（Pd）合金膜「HPM-L111」。本產品是世界首創※１，在100℃左右的低溫範圍內具有較高的氫氣過濾性能的金屬膜。樣品將於2026年3月5日（四）以後開始提供。關於數量，最多每月可提供約100片。本產品將在2026年3月11日（三）至13日（五）於千葉工業大學舉行的公益社團法人日本金屬學會「2026年春季（第178屆）演講大會」的會議上進行發表。另外，將在2026年3月17日（二）至19日（四）於東京國際展覽中心舉行的「H2 ＆ FC EXPO 氫能與燃料電池展」，進行產品及展示板的展示。濾氫鈀（Pd）膜「HPM-L111」濾氫鈀膜是將具有吸儲和過濾氫氣特性的鈀合金加以薄膜化的產品，用於分離和純化高純度氫氣。一般來說，要以金屬膜實現過濾氫氣，需要在高溫（300℃以上）下進行。這次，TANAKA透過對膜表面進行特殊處理，成功開發出即使在100℃以下的低溫範圍內也能發揮出較高的氫氣過濾性能的金屬膜。利用金屬膜進行氫氣純化的課題及「HPM-L111」的研發背景以往產品的「PdCu40」（鈀含有率60％，銅含有率40％的合金）在PdCu系合金膜中具有最高水準的氫氣過濾性能。不過，要發揮原本具有的性能，需要在400℃左右的高溫範圍內使用，額外追加的加熱設備等所增加的成本成為多年來的課題。近年來，隨著氫氣相關技術的發展，在100°C以下的低溫範圍內透過金屬膜進行濾氫的需求日益增長。另一方面，由於金屬膜通常在200℃以下時氫氣從表面向內部滲透的速率會減慢，導致以往金屬膜的氫氣過濾性能顯著下降，在實際應用上帶來了課題。為了解決這些課題，「HPM-L111」採用了TANAKA多年來在貴金屬材料研發所累積的獨家表面處理技術。透過在膜表面形成細微的凹凸結構，並擴增比表面積，提高氫氣的滲透速率，實現了在100℃以下的低溫範圍內氫氣過濾性能的大幅提升。「HPM-L111」的特色在100℃左右的低溫範圍內發揮較高的氫氣過濾性能世界首創可在100℃左右的低溫範圍內進行高純度氫氣純化的金屬膜可望有助於氫氣感測器的高精度化可高速去除機器內部所產生的氫氣以往產品「PdCu40」的剖面圖「HPM-L111」的剖面圖 品名厚度寬度長度建議溫度預計用途HPM-H310（PdCu40）>10μm<120mm<100mm400°C・氫氣純化HPM-H211（PdCu39）>10μm<120mm<100mm300°C・氫氣純化HPM-L111>10μm <35mm<85mm100°C・氫氣感測器・燃料電池・真空設備的氫氣去除・氫氣純化「HPM-L111」與以往產品的比較及建議用途一覽HPM-L111的氫氣滲透係數的溫度依賴性在100℃以下低溫範圍內進行的高純度濾氫用途，預計會有氫氣感測器、燃料電池以及真空設備的氫氣去除等。在氫氣感測器方面，阻隔不必要的氣體有助於提升檢測精度；在真空設備等方面，則可在保持接近常温與低溫的稼動環境的同時，進行內部氫氣的去除。此外，透過省去以往不可或缺的300℃以上的加熱程序，減少加熱能量，對實現碳中和做出貢獻。TANAKA將透過提供本產品，支持打造綠色且高效率的氫能社會。（※1）：截至2026年3月5日，經本公司調查（摘自濾氫薄膜的專利和論文調査）關於TANAKATANAKA自1885年（明治18年）創業以來，營業範圍以貴金屬為中心，並以此展開廣泛活動。在日本國內，以最高水準的貴金屬交易量為傲的TANAKA，長年以來除了進行產業用貴金屬產品的製造和販售外，並提供資產用與珠寶用的貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2024年度（2024年12月止）的合併營業額為8,469億日圓，擁有5,591名員工。產業事業全球網站https://tanaka-preciousmetals.com產品諮詢表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處TANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: http://www.acnnewswire.com/docs/files/20260305_CT.pdf  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Tashkent, Uzbekistan, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) -�FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium � a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework.Why Uzbekistan - Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter.Asterium's project is designed to operate fully within this framework.What Was Deployed - FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium's business model. The core deployment covers three key layers:Banking infrastructure � management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems.Digital asset infrastructure � crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan's Mirasmanda ledger for HUMO asset support.Compliance and exchange � a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off.The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards � all within a regulated environment.How the Partnership Works - FinHarbor operates as Asterium's strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion."This project required deep architectural customization � from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards," said Ilya Podoynitsyn, CEO of FinHarbor. "The core phase is complete, and we are already scaling the platform with new products and business use cases."��What's Next - With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform's functionality to support additional business lines built on the deployed stack.About FinHarborFinHarbor provides modular technology infrastructure for launching compliant financial products � from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets.Social LinksLinkedIn: https://www.linkedin.com/company/finharbor/Blog: https://www.finharbor.com/blog�Media contactBrand: FinHarborContact: Media teamWebsite: https://www.finharbor.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com